Peginterferon alfa-2a Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Peginterferon alfa-2a Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
494
Registered trials
189
Result records
1
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Peginterferon alfa-2a can convert its Interferons profile and Type I IFN Receptor biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Peginterferon alfa-2a (query alias: peginterferon alfa-2a) |
|---|---|
| Modality / target | Interferons; Type I IFN Receptor; IFNAR agonists |
| Highest global status | Approved |
| Originator | F. Hoffmann-La Roche Ltd. |
| Active developers | Pharma& Schweiz GmbH, Shanghai Roche Pharmaceuticals Ltd., Roche Pharma (Schweiz) AG |
The MCP disease footprint includes Hepatitis B, Hepatitis C, Hepatitis B, Chronic. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07135349 | Phase 2 | Active, not recruiting | 209 | 1. The proportion of participants who meet the NUC discontinuation criteria at Week 72 in participants with baseline HBsAg ⩽ 3000 IU/mL and HBeAg-negative. |
| NCT07288112 | Phase 1/2 | Recruiting | 35 | Phase I: To evaluate the number of dose limiting toxicities reported |
| NCT06144697 | Phase 1 | Terminated | 267 | Incidence of adverse events (AEs) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Ten‐Year Follow‐Up After 96 Weeks Treatment With Peginterferon Plus Tenofovir in Hepatitis D (HIDIT‐II): Improved Clinical Outcome After Combination Therapy
Phase 2; n=107; evaluation: Positive. Reported fields: Incidence(liver-related endpoints) = 34.0 % ; Incidence(liver-related endpoints) = 14.0 %
A Phase II, Randomised, Adaptive, Open-Label Platform Trial To Evaluate Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B
Phase 2; n=281; evaluation: not stated. Reported fields: Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at 24 Weeks Post-End of Treatment (EOT) = 6.7 percentage of participants (95% Confidence Interval, 0.8 - 22.1); Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at 24 Weeks Post-End of Treatment (EOT): Difference in Response Rate = 7.2(95% CI, -2.1 to 16.4); Difference in Response Rate = 3.5(95% CI, -3.1 to 10); Difference in Response Rate = 24.3(95% CI, 9 - 39.5); Difference in Response Rate = 12.3(95% CI, 1.3 - 23.3); Difference in Response Rate = 0(95% CI, 0 - 0); Difference in Response Rate = 6.7(95% CI, -2.2 to 15.7); Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at 24 Weeks Post-End of Treatment (EOT) = 23.3 percentage of participants (95% Confidence Interval, 9.9 - 42.3)
A Study to Evaluate Safety and Efficacy of Boceprevir-response Guided Therapy in Controlled HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin Eudra CT2012-003984-23
Phase 3; n=108; evaluation: not stated. Reported fields: -; -; Number of participants achieving SVR = 66 Participants
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Peginterferon alfa-2a addresses Hepatitis B, Hepatitis C, Hepatitis B, Chronic. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Interferons—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2021-02-18 | zr pharma& GmbH signed an agreement with F. Hoffmann-La Roche Ltd to acquire the worldwide rights of Pegasys® (peginterferon alfa 2a) excluding China and Japan. | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
